Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 845 Module #1 > Lecture 52 + 53 - Antipsychotics > Flashcards

Lecture 52 + 53 - Antipsychotics Flashcards

1
Q

HISTORY AND BACKGROUND OF TREATING SCHIZOPHRENIA

A

 Early 1900’s: Brain disease
 Now: Disease of nature/nurture
 Before 1950’s: Treatments included sedation, lobotomy, ECT, and Rauwolfia alkaloids used in Hindu Medicine
 1950’s: Reserpine
 1952: Phenothiazines (chlorpromazine): Out-patient therapy-emptying mental hospitals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

GENERAL CONSIDERATIONS OF SCHIZOPHRENIA

A

 Antipsychotic = Neuroleptic = Anti-Schizophrenic
 Severe illness, most debilitating of psychotic
disorders
 Affects 1% of population
 Onset age 15-20 years old
 Not Split personality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ETIOLOGY OF SCHIZOPHRENIA

A

Neurodevelopmental/anatomical In utero/adolescence-increased ventricle size and changes in gray and white matter
Genetics-neuronal growth, migration of neurons (twin studies, families-multiple genes)
 Environmental- Birth complications, infections
Gene-Environment Interaction COMT-marijuana
Neurodevelopment-Environment Interaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

SYMPTOMS

A

postive
negative
cognitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Postive Symptoms

A

Respond well to drug therapy – Examples: hallucinations, delusions, bizarre behavior, thought disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Negative Symptoms

A

Little response to drug therapy, newer agents are better
– Examples: blunted emotion, poor self care, social withdrawal, poverty in speech

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cognitive Symptoms

A

decrease in cognitive function
Involves D1 receptors and glutamate receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NEUROTRANMITTER HYPOTHESES

A

 Dopamine: First to be developed, but incomplete
 Serotonin: Based on mechanism of LSD and mescaline
 Glutamate: Based on phencyclidine and ketamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SEROTONIN HYPOTHESIS OF SCHIZOPHRENIA

A
  1. LSD and mescaline were identified as 5HT agonists, inspired search for ‘endogenous’ hallucinogens
  2. Pharmacological studies with 5HT receptors identified 5HT2A receptor as mediator of hallucinations
  3. Antagonism and inverse agonism linked to antipsychotic activity
  4. 5HT2A receptors modulate dopamine release in cortex, limbic region, and striatum
  5. 5HT2A receptors modulate glutamate release and NMDA receptors
  6. 5HT2C agonists may be beneficial in schizophrenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

GLUTAMATE HYPOTHESIS OF SCHIZOPHRENIA

A
  1. Glutamate is major excitatory neurotransmitter
  2. Phencyclidine and ketamine, noncompetitive inhibitors of NMDA receptors exacerbate psychosis and cognition deficits
  3. LY2140023-mGLuR2/3 agonist effective in schizophrenia
  4. Ampakine (AMPA receptors)-effective in animal models
  5. GlyT inhibitors (under development
    as adjuncts)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA

A
  1. D2 receptor antagonists - Binding and therapeutics; strong correlation receptor binding affinity vs. clinical effectiveness
  2. Dopaminergic agents (e.g. L-DOPA, amphetamine, bromocriptine) exacerbate symptoms of schizophrenia
  3. Increased D2 receptor density in treated and untreated patients of schizophrenia
  4. Imaging studies-increased DA release and receptor occupancy in patients
  5. Dopamine metabolites in CSF - D2 receptor antagonists initially increase metabolites in the CNS and later decrease metabolites in CNS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DETERMINING BINDING AFFINITY

A

 Binding Affinity: Intermolecular force between ligand and receptor
 Kd/Ki: Estimated concentration at which 1⁄2 of the receptors are occupied
 Saturation binding experiments – Vary concentration of radio-labeled ligands
 Competition binding experiments
– Constant radioligand (hot) concentration competing with unlabeled ligand (cold)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

RECEPTORS ANTAGONIZED BY ANTIPSYCHOTICS: major

A

Dopamine (5 dopamine receptors)
D1-like receptors (D1 and D5)
D2-like receptors (D2, D3, and D4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

RECEPTORS ANTAGONIZED BY ANTIPSYCHOTICS: newer agents

A

Serotonin (5HT):
5HT2A Receptor Antagonists: clozapine, olanzapine, and risperidone
Older Agents: chlorpromazine, haldol, thioridazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

RECEPTORS ANTAGONIZED BY ANTIPSYCHOTICS: minor

A

Norepinephrine (NE): alpha1 Receptor Blockade: hypotension, sedation; alpha2 Receptor Blockade: may be helpful in therapy
Acetylcholine (ACh): Muscarinic receptors -anticholinergic effects (clozapine, thioridazine)
Histamine: H1 Receptor Antagonists: sedation, weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which receptor is key for therapeutic effectiveness?

A

There is no clear pattern: multiple receptors; individualize therapy based on patient response; unable to predict effectiveness of each therapy for individual patient
multiple receptors –> many SE –> poor adherence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

BINDING AFFINITY VS. CLINICAL DOSE

A

Correlation between binding potency and clinical effectiveness for D2 receptors, therefore more effective drug target
Most antipsychotic drugs are receptor antagonists
Dopamine (D1, D2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Antagonist actions at synapse

A

D2 receptors: Modulates synthesis and release of dopamine, block D2 receptor antagonist, get an increase in the synthesis and release of DA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

DOPAMINE PHYSIOLOGY & FUNCTION

A

Actions of D2 Antagonists in CNS:
 Basal Ganglia (Nigrostriatal Pathway): Motor effects, extrapyramidal symptoms (EPS)
 Mesolimbic: Primary therapeutic effects (only ones we really want to block)
 Mesocortical: Hypofunction in schizophrenia, antagonists may exacerbate cognitive deficits
 Hypothalamus and Endocrine Systems: D2
receptor blockade in endocrine system
 Medulla: Chemoreceptor trigger zone; D2 antagonists are anti-emetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Receptor Occupancy and PET

A

PET scan using [18F] fallypride in the absence (baseline) or presence of increasing doses of the antipsychotic drug aripiprazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Receptor Occupancy and Antipsychotic Effects

A

see antipsychotic effect threshold at 70%; EPS threshold at 80%, start to see extrapyramidal sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

DRUG-INDUCED MOVEMENT DISORDERS (D2 Antagonism) - extrapyramidal symptoms

A
  1. Extrapyramidal Symptoms (EPS) 30-50%:
     Occur early, days/weeks, reversible
     Symptoms:
    – Dystonia – Increased muscle tone
    – Pseudoparkinsonism – Muscle rigidity
    – Tremor
    – Akathisia – Restlessness
    Unfortunately most patients will experience EPS as a result of long term antipsychotic drug therapy; important monitoring parameter
     Drug Therapy for EPS:
    – Benztropine (Cogentin), trihexyphenidyl (Artane), or akineton (Biperiden) – Anticholinergic agents
    – Diphenhydramine (Benadryl) – Antihistamine
    – Amantadine (Symmetrel) – Dopamine releasing agent
    – Propranolol – used for akathisia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

NEURONS INVOLVED IN EPS:

A

dopamine: inhibitory
acetylcholine: excitatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

DRUG-INDUCED MOVEMENT DISORDERS (D2 Antagonism) - tradive dyskinesia

A
  1. Tardive Dyskinesia (20-40%):
     Occur late, months to a year, IRREVERSIBLE!!!
    Symptoms:
    – Mouth – Rhythmic involuntary movements
    – Choreiform – Irregular purposelessness
    – Athetoid – Worm-like
    – Axial hyperkinesias – “To-and-fro” movements
     Unknown MOA: Neuroadaptive response- Antagonist- induced supersensitivity of receptors to dopamine?
    Monitoring: AIMS (Abnormal Involuntary Movement Scale) rating scale; check every 6 months
    Treatment: Prevention! Use the least risky agent at the lowest dose possible and monitor
  2. Reduce dose of current agent
  3. Change to a different drug; possibly a newer agent
  4. Eliminate anticholinergic drugs
  5. VMAT inhibitors
     Newer Drug Therapies for TD: VMAT2 Inhibitors
    – Tetrabenazine (Xenazine) for Huntington’s chorea
    – Valbenazine (Ingrezza) for TD
    – Deutetrabenazine (Austedo) for TD and Huntington’s chorea
    prevent dopamine from being packaged into synaptic vesicles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

DRUG-INDUCED MOVEMENT DISORDERS (D2 Antagonism) - neuroleptic malignant syndrome

A
  1. Neuroleptic Malignant Syndrome (NMS):
     SeriousandRAPID;10%Fatality
     Symptoms:
    – EPS symptoms with fever
    – Impaired cognition – Agitation, delirium, coma
    – Muscle rigidity
     Treatment: Restore dopamine balance
    – Discontinue drug
    – DA agonists, diazepam, or dantrolene (skeletal muscle relaxant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

THERAPEUTIC USES OF ANTIPSYCHOTIC DRUGS

A

 Treatment of psychosis:
– 2-3 weeks for effectiveness
– 6 weeks to 6 months maximal efficacy
 Other Mental Disorders
– Anxiety = Overkill!
– Mood Disorders: Mania = Secondary to lithium, used in combination; Depression = When accompanied by agitation and delusions
– Tourette’s syndrome-tics, vocalizations: Treat with Pimozide (Orap)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

MISCELLANEOUS USES: huntington’s chorea

A

tetrabenazine, deutetrabenazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

MISCELLANEOUS USES: intractable hiccups

A

chlorpromazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

MISCELLANEOUS USES: alcohol withdrawal (hallucinations)

A

haloperidol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

MISCELLANEOUS USES: nausea and vomiting

A

metoclopramide, promethazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

MISCELLANEOUS USES: potentiation of opiates and sedatives

A

droperidol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

PHARMACOLOGICAL EFFECTS OF THE ANTIPSYCHOTIC DRUGS

A

 Behavioral Effects: Unpleasant in normal subjects or reversal of signs and symptoms of psychosis in affected individuals
 “Neuroleptic” Syndrome: Suppress emotions, reduce initiative and interest, affect; may resemble negative symptoms
 Block conditioned avoidance responses in animal studies
 Decreased spontaneous activity, aggressive, and impulsive behavior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Adverse Pharmacological Effects types

A

autonomic
CNS
endocrine system
other

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Autonomic mechanism and manifestations

A

Muscarinic cholinoceptor blockade: Loss of accomodation, dry mouth, difficulty urinating, constipation
Alpha adrenoceptor blockade: Orthostatic hypotension, impotence, failure to ejaculate

35
Q

CNS mechanism and manifestations

A

Dopamine receptor blockade: parkinson’s syndrome, akathasia, dystonias
Supersensitivity of dopamine receptors: tardive dyskinesia
Muscarinic blockade: toxic-confusional state
Histamine (H1) receptor blockade: sedation

36
Q

Endocrine system mechanism and manifestations

A

Dopamine receptor blockade resutling in hyperprolactinemia: amenorrhea-galactorrhea, infertility, impotence

37
Q

Other mechanism and manifestations

A

Possibly combined H1 and 5HT2c blockade: weight gain

38
Q

PRECAUTIONS AND CONTRAINDICATIONS

A

 Cardiovascular
 Parkinson’s Disease
 Epilepsy (e.g. Clozapine will lower seizure threshold)
 Diabetes (for newer agents)

39
Q

Typical First Generation Antipsychotics

A

More movement problems
Increased EPS and tardive dyskinesia due to strong D2 block

40
Q

PHENOTHIAZINE NUCLEUS

A

1st antipsychotic: chlorpromazine
R10: requires 3 atom chain (allows nitrogen to bind receptor)
2 atom chain = antihistamine
R2: important for potency

41
Q

PHENOTHIAZINE NUCLEUS examples

A

 Aliphatic Phenothiazines
 Piperidine Phenothiazines
 Piperazine Phenothiazines

42
Q

Aliphatic phenothiazines

A

 Aliphatic Phenothiazines:
– *Chlorpromazine (Thorazine) - No longer 1st line therapy
 Aliphatic Phenothiazines: Used for H1 antagonist properties
– *Promethazine (Phenergan) - Also other indications, N/V

43
Q

Piperidine Phenothiazines

A

 Piperidine Phenothiazines:
– *Thioridazine (Mellaril) - Sedation, hypotension; anticholinergic, many SE

44
Q

Piperazine Phenothiazines

A

 Piperazine Phenothiazines:
– *Fluphenazine (Permitil, Prolixin) - EPS
– *Prochlorperazine (Compazine) - Antiemetic
– *Perphenazine (Trilafon) -
 CATIE studies: Perphenazine and anticholinergic vs. several newer agents

45
Q

ANTIPSYCHOTICS

A

thioxanthines
butyrophenones

46
Q

Thioxanthines

A

*Thiothixene (Navane) - Modest EPS

47
Q

Butyrophenones

A

*Haloperidol (Haldol) - EPS

48
Q

Miscellaneous Antipsychotics

A

 *Molindone (Moban)
– ModerateEPS
– Zyprexa or Risperidal vs. Moban + Benztropine: Found weight gain/metabolic problems in newer agents; adherence issues
 *Pimozide (Orap)
– Tourette’sdisease-tics,vocalizations

49
Q

Key points of chlorpromazine

A

1st Antipsychotic, antihistamine side effects

50
Q

Key points of promethazine

A

Antihistamine, antiemetic

51
Q

Key points of thioridazine

A

Many SE: anticholinergic, sedation, sexual dysfunction, cardiovascular

52
Q

Key points of fluephenazine

A

EPS

53
Q

Key points of proclorperazine

A

antiemetic

54
Q

Key points of perphenazine

A

CATIE studies: combo with anticholinergic

55
Q

Key points of thiothixene

A

modest EPS

56
Q

Key points of haloperidol

A

EPS

57
Q

Key points of molindone

A

moderate EPS

58
Q

Key points of pimozide

A

tourette’s disease, suppress motor and vocal tics

59
Q

Atypical/Second Generation Antipsychotics

A

Reduced EPS
Efficacy for Negative symptoms?
Similar or enhanced 5HT2A receptor antagonism vs D2 (see “Serotonin Hypothesis of Schizophrenia”)
More metabolic problems
Linked to diabetes (greater risk in patients < 50)
 Olanzapine, Clozapine,
 Less evidence in Quetiapine and Risperidone

60
Q

ATYPICAL/2nd GENERATION ANTIPSYCHOTICS

A

clozapine
olanzapine
loxapine
quetiapine
ziprasidone
asenapine
lurasidone
pimavanserin
aripiprazole

61
Q

Clozapine

A

*Clozapine (Clozaril)
-1st atypical antipsychotic
-Very effective
 Agranulocytosis
– Occurs in 1-2% within 6 months (weekly blood monitoring) – 2nd or 3rd line therapy
 Side Effects: Anticholinergic, Antihistamine
– Reduced D2 potency = decreased movement disorders
– Risk of diabetes

62
Q

Olanzapine

A

-Weight gain
-Less likely to causes N&V
-Less likely to cause movement disorders
-Risk of diabetes

63
Q

Loxapine

A

-Older agent
-Metabolite = Amoxipine (Ascendin) Inhibits NET –> Antidepressant

64
Q

Quetiapine

A

-Metabolite w/ antidepressant activity
-5HT2A and D2 (low antimuscarinic)
-Low EPS
-Hypotension (α1)
-Sedation (H1)
-Risk of diabetes

65
Q

Ziprasidone

A

-5HT2A , D2, α1 affinity
-Prolongs QT interval
-Long acting formulation under study

66
Q

Asenapine

A

-5HT2A and D2
(nM affinity at most 5HT, α, DA, and histamine receptors)

67
Q

Lurasidone

A

5HT2A and D2
Less weight gain and metabolic effects (vs olanzapine)
Fast onset (days without titration)
Low doses similar effectiveness to high doses

68
Q

Pimavanserin

A

Inverse agonist 5HT2A (40x vs 5HT2C)
Used for Parkinson disease psychosis

69
Q

Aripiprazole

A

-High affinity for 5HT2 and D2 (D2 actions are dopaminergic-state dependent and/or it is functionally selective)
-Partial agonist at 5HT1A receptors (being used in depression)
-Moderate affinity for D4, α, and histamine receptors
-Side Effects: Weight gain, low risk for D2 effects
-Prodrug: aripiprazole lauroxil, given q 4-8 weeks

70
Q

ATYPICAL ANTIPSYCHOTICS examples

A

risperidone
paliperidone
iloperidone

71
Q

Risperidone

A

-Specifically and structurally designed to be both a 5HT2A and D2 receptor antagonist! (Rational drug design)
-Relatively low EPS at <8 mg/day
-Weight gain; some sedation

72
Q

Paliperidone

A

9-hydroxyrisperidone

73
Q

Iloperidone

A
  • structurally related to risperidone
  • very potent at alpha1 receptors (0.5 nM vs 5 nM at 5HT2A and D2)
74
Q

D2/D3 receptor partial agonists

A

brexiprazole
cariprazine
lumateperone

75
Q

Brexpiprazole

A

a D2/D3 partial agonist with supposedly less akathisia vs. aripiprazole.
Schizophrenia and as an adjunct to antidepressants for major depression
Partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors

76
Q

Cariprazine

A

also a D2/D3 partial agonist with greater affinity for D3. Weak partial agonist activity at 5-HT1A. Akathisia is high
Schizophrenia, mania, bipolar disorder

77
Q

Lumateperone

A

partial D2 agonist presynaptic receptors/antagonist at postsynaptic receptors (5HT2A antagonist)

78
Q

Clozapine key points

A

1st Atypical antipsychotic, agranulocytosis, risk of diabetes, superior efficacy

79
Q

Olanzapine key points

A

Weight gain, risk of diabetes

80
Q

Quetiapine key points

A

Metabolite w/ antidepressant activity; hypotension, sedation

81
Q

Risperidone key points

A

5HT2A/D2 receptor antagonist

82
Q

Ziprasidone key points

A

5HT2A/D2, α1 affinity; prolongs QT interval

83
Q

Lurasidone key points

A

5HT2A/D2, reduced metabolic effects, rapid titration

84
Q

Aripiprazole key points

A

High 5HT2A/D2 affinity, partial agonist activity

PHRM 845 Module #1 (50 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions